Atlas Trials

Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

Clinical trial NCT03178071 · NO_LONGER_AVAILABLE

Trial details

NCT number
NCT03178071
Sponsor
Pfizer
Status
NO_LONGER_AVAILABLE
Study type
EXPANDED_ACCESS
Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.